Mulvany – who left BenevolentAI when it listed on the Amsterdam stock exchange in 2022 and retains a sizeable stake in the ...

Sports marketing offers healthcare brands an alternative channel to reach their audiences and align with the strong brand ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of their value on a report that a joint takeover ...

The result of the NEXUS trial means that the two companies can now press on with their plan to refile for EU approval of the ...

Apimostinel has a similar mode of action to ketamine and derivatives like Johnson & Johnson's Spravato (esketamine) – ...

Crucially for the Netherlands-based biopharma company, the FDA has said that the composite Unified Huntington's Disease ...

Launching a new pharmaceutical product is a high-stakes endeavour. Over the past decade, nearly 40% of launches have fallen ...

"Today marks a significant milestone in women's health in the US as we are thrilled to see that ProVate is now available for ...

With billions invested and digital health initiatives on the rise, why do so few pharma-tech partnerships achieve lasting ...

A 26-year-old man has been charged with murder in connection with the fatal shooting last week of UnitedHealth chief ...

"KEYLYNK-001 is the first positive phase 3 trial for Keytruda plus Lynparza, highlighting our commitment to research that may ...

The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...